Please assess the completion status of the following clinical trial:

Trial Title: Brain Imaging and Treatment Studies of the Night Eating Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men and women suffering from NES~* ages 18 to 70 years~* BMI greater than 18.5 kg/m2~Exclusion Criteria:~* Children or adolescents \<18 years~* persons older than 70~* patients with diabetes mellitus~* thyroid disease and other endocrine and metabolic disorders~* use within the past month of any psychotropic medication, oral steroids, diuretics or hypnotics~* current anorexia nervosa or bulimia nervosa~* participation in an organized weight reduction program~* use of antiobesity medication~* an occupation that involves night shifts or other unusual time requirements -Major Depressive Disorder (judged severe)~* Bipolar Disorder~* suicidal risk~* current or past psychosis~* substance use or abuse disorder within the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Night Eaters (Type: EXPERIMENTAL): Subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing. For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment. Escitalopram oxalate (Lexapro) open-label treatment will last 12 weeks. Dosing will start at 10 mg and increase to 20 mg per day flexibly. Treatment will be discontinued starting at 12 weeks under the supervision of our study physician.
- Control Subjects (Type: NO_INTERVENTION): At the beginning of the study, control subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing.~An ADAM SPECT or SPECT-CT study of SERT binding will be conducted which will compare SERT binding of the 10 control subjects with that of the 30 night eating subjects. The first procedure will be to assess SPECT or SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls.

Based on this trial design, predict the completion outcome and termination type (if applicable).